These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695 [TBL] [Abstract][Full Text] [Related]
7. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807 [TBL] [Abstract][Full Text] [Related]
8. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C. Fraile-López M; Alvarez-Navascués C; González-Diéguez ML; Cadahía V; Chiminazzo V; Castaño A; Varela M; Rodríguez M Gastroenterol Hepatol; 2023 Dec; 46(10):754-763. PubMed ID: 36716928 [TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002 [TBL] [Abstract][Full Text] [Related]
10. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696 [TBL] [Abstract][Full Text] [Related]
11. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803 [TBL] [Abstract][Full Text] [Related]
12. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847 [TBL] [Abstract][Full Text] [Related]
13. Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients. Liu YC; Cheng YT; Chen YC; Hsieh YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Dig Dis Sci; 2023 Jan; 68(1):323-332. PubMed ID: 35895234 [TBL] [Abstract][Full Text] [Related]
14. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral. Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Direct-acting Agents After Liver Transplantation A Real-life Study in Rio de Janeiro. Pinto L; Balbi E; Halpern M; Carius L; Roma J; Cardoso SW; Grinsztejn B; Veloso VG; Pacheco L; Perazzo H Arch Med Res; 2022 Sep; 53(6):585-593. PubMed ID: 36114037 [TBL] [Abstract][Full Text] [Related]
16. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
17. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. Broquetas T; Herruzo-Pino P; Mariño Z; Naranjo D; Vergara M; Morillas RM; Forns X; Carrión JA Liver Int; 2021 Nov; 41(11):2733-2746. PubMed ID: 34525253 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501 [TBL] [Abstract][Full Text] [Related]
19. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Mendizabal M; Piñero F; Ridruejo E; Herz Wolff F; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Videla Zuain MG; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Rubinstein F; Cheinquer H; Silva M; ; Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2554-2563.e3. PubMed ID: 32113892 [TBL] [Abstract][Full Text] [Related]
20. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders. Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]